TABLE 1.

Cell viability in the presence of inhibitors^a

Cell type	% Viability ± 1 SD in the presence of:
	PRO 2000	D2S	DexS	Dex	DMSO	P-80	Pcr-400
HeLa	103 ± 2	106 ± 3	103 ± 2	102 ± 5	99 ± 2	102 ± 5	99 ± 6
293T	98 ± 3	95 ± 4	90 ± 5	93 ± 2	93 ± 2	99 ± 4	99 ± 2
293T-GFP	104 ± 2	95 ± 3	84 ± 5	94 ± 3	104 ± 9	91 ± 9	109 ± 6
Ghost	110 ± 11	102 ± 3	90 ± 9	98 ± 8	89 ± 5	104 ± 13	105 ± 0
Jurkat	93 ± 6	98 ± 1	99 ± 1	100 ± 1	102 ± 2	104 ± 4	101 ± 4
CD4+ primary cells	93 ± 2	106 ± 3	96 ± 5	108 ± 4	108 ± 4	95 ± 3	117 ± 15
C91PL	106 ± 4	115 ± 10	93 ± 6	101 ± 6	96 ± 10	101 ± 3	101 ± 4
MT-2	100 ± 1	96 ± 7	95 ± 2	97 ± 3	103 ± 2	96 ± 3	104 ± 1

^aInhibitors were added to cells at 100 μM for polyanions or 10 μM for peptides, and metabolic function after 3 days was measured by the MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assay.